Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 53Neoplasms 44Prostatic Neoplasms 43Breast Neoplasms 38Neoplasm Metastasis 21Unspecified Adult Solid Tumor, Protocol Specific 19Lung Neoplasms 18Head and Neck Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Ovarian Neoplasms 15Advanced Solid Tumors 11Stomach Neoplasms 9Sarcoma 9Pancreatic Neoplasms 9Solid Tumor 8Melanoma 8Esophageal Neoplasms 8Carcinoma, Ovarian Epithelial 8Urinary Bladder Neoplasms 7Fallopian Tube Neoplasms 7Colorectal Neoplasms 7Small Cell Lung Carcinoma 6Salivary Gland Neoplasms 6Esthesioneuroblastoma, Olfactory 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Renal Cell 5Breast Neoplasms, Male 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × HER-2 Gene Amplification × Docetaxel × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡